Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-07-18 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
股票交易异常波动公告的更正公告
Director's Dealing Classification · 90% confidence The document is a correction announcement regarding a previously disclosed announcement about abnormal stock trading fluctuations and a plan for directors and senior management to increase their shareholdings. It corrects the disclosed amount of planned share purchases by insiders. The document is short (1289 characters) and does not contain financial statements or detailed financial data. It is an announcement correcting a prior disclosure related to insider share transactions, not the original insider transaction report itself. Therefore, it fits best under Director's Dealing (DIRS) as it relates to directors and senior management shareholding changes, but since it is a correction notice, it is still about insider dealings. The document is not a full report but a correction to a prior announcement about insider transactions.
2018-07-18 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Shenzhen BGI Genomics Co., Ltd. regarding abnormal stock price fluctuations over two trading days. It includes explanations about the situation, clarifications on previously disclosed information, confirmation of no undisclosed material information, and risk warnings to investors. The document does not contain financial statements, detailed financial performance data, or management discussion of results. It is a regulatory disclosure about stock trading activity and company information compliance, typical of a Regulatory Filings (RNS) category. The document length is short (1530 characters), and it is not an announcement of a report publication but a standalone disclosure. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-07-17 Chinese
关于部分董事、高级管理人员增持公司股份计划的公告
Director's Dealing Classification · 100% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding a plan by some of its directors and senior management to increase their holdings in the company's shares. It details the participants, the amount to be invested, the timeframe, and the purpose of the share increase. There is no financial report, earnings data, or regulatory certification. The content focuses on insider share transactions by company directors and executives. Therefore, this fits the category of Director's Dealing (DIRS). The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS.
2018-07-17 Chinese
关于全资子公司申报医疗器械注册获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. regarding the acceptance of medical device registration applications for four products by a regulatory authority (Hubei Food and Drug Administration). It describes the current status of the registration process and its potential impact on the company. The document is short (1465 characters) and does not contain financial data, financial statements, or detailed financial analysis. It is an announcement about regulatory approval progress rather than a financial report or detailed management discussion. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it does not mention any report being published or attached. The content is regulatory in nature, related to compliance and approvals, so the best fitting category is Regulatory Filings (RNS).
2018-07-16 Chinese
关于媒体报道的澄清公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. clarifying media reports about their non-invasive prenatal genetic testing technology and related business activities. It addresses concerns raised by a media report, provides scientific and regulatory context, and reassures investors about the company's practices. The document is relatively short (2954 characters) and serves as a clarification or rebuttal announcement rather than a financial report, earnings release, or regulatory filing. It does not contain financial data, management changes, voting results, or legal proceedings. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category that covers miscellaneous company disclosures that do not fit other specific categories.
2018-07-13 Chinese
2018年半年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2018年半年度业绩预告' which translates to '2018 Half-Year Performance Forecast'. It provides estimated financial results for the period January 1, 2018 to June 30, 2018, including expected net profit and revenue growth percentages. It explicitly states that the forecast is unaudited and that detailed financial data will be disclosed in the 2018 half-year report. The document is short (1194 characters) and serves as a preliminary earnings forecast rather than a full interim report containing actual financial statements or detailed analysis. Therefore, it is best classified as an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. H1 2018
2018-07-12 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.